FirebrickPharma

26 August 2025

ASX Announcement

License Agreement Executed for Singapore, Malaysia, Brunei and Mauritius

- **Innorini Pte Ltd has been appointed exclusive licensee for Nasodine products in Singapore, Malaysia, Brunei and Mauritius**
- **New agreement expected to significantly reduce Firebrick's marketing expenses in FY26 and open up new markets for the sale of Nasodine products**

For personal use only

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to announce that it has executed a License and Distribution Agreement (**Agreement**) with Innorini Pte Ltd (**Innorini**) covering sales of Nasodine products in four countries: Singapore, Malaysia, Brunei and Mauritius (the **Territory**).

Under the Agreement, Innorini will have the exclusive right to distribute, promote and sell Nasodine® Nasal Spray and all future Nasodine brand products (the **Products**) in the Territory. Nasodine Nasal Spray is already sold in Singapore and Innorini is pursuing the necessary regulatory approvals for the product to be imported and sold in the other three countries.

The Company previously announced a Marketing Representation Agreement (**MRA**) with Innorini covering the marketing of Nasodine Nasal Spray to healthcare professionals (**HCPs)** in Singapore (announcement 31 October 2024). The Agreement replaces the MRA and extends the marketing activities of Innorini to include all distribution, promotion and sale in Singapore, including management of the existing relationships with DKSH and Guardian in Singapore (announcement 25 November 2024). The Agreement also extends the territory to include the other three countries.

"Innorini has been an excellent partner for us in Singapore, and we are now pleased to expand their marketing to include new countries where we understand that Nasodine Nasal Spray can be sold using the same package and labelling as in Singapore," said Firebrick Executive Chairman, Dr Peter Molloy. "Importantly, under the new Agreement, Innorini will bear all marketing costs in the Territory from 1 January 2026, which will significantly reduce Firebrick's advertising and promotion expenditure compared with FY25" (refer Quarterly Activity Report announcement 23 July 2025).

Rishi Nandiraju, Managing Director of Innorini, said:

"We are proud to deepen our partnership with Firebrick Pharma as their licensee across Singapore, Malaysia, Brunei, and Mauritius. This expansion reflects our shared commitment to bringing innovative, clinically proven solutions like Nasodine to markets where there is a clear need for effective, science-driven healthcare products. At Innorini, we believe this collaboration will not only strengthen our regional presence but also help us empower healthcare providers and patients with greater access to trusted therapies."

The Agreement also provides Innorini with the right to manufacture Products anywhere in the Territory. This provides for future supply flexibility and reduced manufacturing, shipping and other costs currently associated with importing Products from Australia.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

Detailed terms of the Agreement

The success of the distribution by Innorini will drive any revenue received by Firebrick as there are no commitments as to minimum quantities to be sold.

Term: 2 years with renewals for subsequent 2-year terms by mutual agreement.

Termination: The Agreement may be terminated prior to the end of the Term or any subsequent term, with immediate effect, if:

- Either Party is acquired by a third party, or a third party gains effective control of the affairs of a Party;
- Either Party is in breach of any terms of the Agreement, and the breach remains unremedied thirty (30) days after notice of said breach is received by the Party; or
- Either Party becomes bankrupt, enters administration or liquidation proceedings, or otherwise becomes insolvent.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

Media enquiries:
Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:
Investors@firebrickpharma.com

For personal use only